These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 36774974)

  • 1. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
    Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
    ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
    Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
    Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy.
    Tian D; Qin F; Zhao H; Zhang C; Wang H; Liu N; Ai Y
    Colloids Surf B Biointerfaces; 2021 Jun; 202():111681. PubMed ID: 33714187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer.
    Chen Y; Gong L; Cao Y; Liu Z; Wang Y; Cheng H; Feng Y; Yao S; Yin Y; Wu Z; Huang Z
    J Control Release; 2024 Feb; 366():395-409. PubMed ID: 38184235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
    Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
    J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update to experimental and clinical aspects of tumor-associated macrophages in cancer development: hopes and pitfalls.
    Salmaninejad A; Layeghi SM; Falakian Z; Golestani S; Kobravi S; Talebi S; Yousefi M
    Clin Exp Med; 2024 Jul; 24(1):156. PubMed ID: 39003350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy.
    Gong Y; Gao W; Zhang J; Dong X; Zhu D; Ma G
    J Nanobiotechnology; 2024 Jun; 22(1):341. PubMed ID: 38890636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.
    Chen S; He Y; Huang X; Shen Y; Zou Q; Yang G; Fu L; Liu Q; Luo D
    J Nanobiotechnology; 2024 Jun; 22(1):348. PubMed ID: 38898486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer.
    Jian H; Wang X; Song P; Wu X; Zheng R; Wang Y; Zhang H
    Acta Biomater; 2022 Mar; 140():518-529. PubMed ID: 34923096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles.
    Chong L; Jiang YW; Wang D; Chang P; Xu K; Li J
    J Nanobiotechnology; 2023 Oct; 21(1):401. PubMed ID: 37907987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
    Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
    J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy.
    Kang Y; Lim J; Saravanakumar G; Kim J; Park M; Im S; Kim WJ
    J Control Release; 2022 Mar; 343():78-88. PubMed ID: 35065158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
    Gao J; Liang Y; Wang L
    Front Immunol; 2022; 13():888713. PubMed ID: 35844605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.